AMR: IMI’s Enable project reaches endpoints
The IMI project was recently granted a one-year extension to promote further progression of ongoing programmes, while keeping within the original budget of about €100m. ENABLE was formed in 2014 to accelerate the development of new antibiotics for the treatment of difficult-to-treat Gram-negative infections. The project has so far identified five antibacterial leads.
Emerging Antimicrobials and Diagnostics in AMR 2023
International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands